Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) - Global Forecast to 2026
Instant Answers with GPT - Ask Now!
Ask real questions. Get complete answers !
Generating Response ...Updated on : May 24, 2023
The global clinical trials market in terms of revenue was estimated to be worth $38.7 billion in 2021 and is poised to reach $52.0 billion by 2026, growing at a CAGR of 6.1% from 2021 to 2026. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Expanding number of clinical trials along with robust investment in pharmaceutical R&D are some of the key driving factors of the market. Maximum number of pharmaceutical, biopharmaceutical, and medical device companies continue to make large investments to develop novel therapeutics and devices. The R&D-intensive nature of pharmaceutical industry, propels companies to outsource clinical trials for expediating launch of therapeutics to the market.
To know about the assumptions considered for the study, Request for Free Sample Report
Clinical Trials Market Dynamics
Driver: Increase in number of clinical trials
The demand for clinical trial services is anticipated to increase as a result of the significant increase in clinical trials taking place around the world, which will subsequently fuel market expansion. As of June 2021, North America and Europe were home to the most clinical trials, according to the WHO's clinical trials registry. By February 2023, more than 30% of clinical trials had been registered in the US. Decentralized clinical trials have also become more common, rising by more than 25% in 2022. The decentralization of clinical trial components has significantly increased the volume of trials conducted annually.
Challenge: Requirement of unique analytical testing approaches for innovative drug molecules
The race to create novel treatments and secure patent exclusivity through expedited drug development has become increasingly fierce in the pharmaceutical and biopharmaceutical industries over time. Bioanalytical testing, which is the most outsourced process among all the chemistry, manufacturing, and control (CMC) activities, plays a significant role in all stages of pharmaceutical and biopharmaceutical development. To satisfy regulatory requirements and obtain approval for an investigational new drug (IND), CMC data is also crucial. The development of novel drug delivery systems and the diversity of CMC requirements for biopharmaceutical IND present a number of challenges and necessitate a wide range of analytical techniques for testing new drug molecules.
Market Trend: Adoption of artificial intelligence-based tools for drug discovery
The early stages of drug development see significantly higher success rates thanks to the use of artificial intelligence (AI) and machine learning (ML) in the drug discovery process. AI algorithms can quickly identify potential drug candidates because they can process and analyze a large amount of data. Additionally, deep learning systems can be used to create molecules with characteristics that are likely to be effective against a variety of diseases without causing unfavorable side effects. These benefits have encouraged a number of pharmaceutical and biotechnology companies to use AI for drug discovery. Consider Benevolent Ltd. (UK) places special emphasis on using deep learning and natural language processing to comprehend and examine massive amounts of data for drug discovery.
By phase, Phase IV of clinical trials market is expected to grow at a fast pace during the forecast period.
Based on phase, the market is segmented into Phase I, Phase II, Phase III, & Phase IV. Phase III dominated the market, whereas Phase IV registered highest growth rate during the forecast period. Variety of formulations, therapy duration, dosages, and other interactions are studied in this phase as a part of post-marketing surveillance. Increase in number of service providers offering post-marketing surveillance has contributed to the highest growth rate registered by this segment.
By service type, the laboratory services segment accounted for the largest share of the clinical trials market.
Based on service type, the market is segmented into protocol designing, site identification, patient recruitment, laboratory services, bioanalytical testing, analytical testing, clinical trial supply & logistic services, decentralized clinical services, clinical trial data management services, medical device testing services, and other services. Laboratory services are used to provide support to all stages of the drug development process, including clinical development. The quality and efficacy of the products are determined through various qualitative and quantitative processes.
By therapy area, oncology segment dominated the clinical trials market
Based on the therapy area, the market is segmented into oncology, infectious diseases, cardiology, neurology, women’s health, genetic diseases, immunology, and other therapy areas. Oncology segment dominated the market. The list of drugs in development for oncology has increased over the years due to the rising number of clinical trials and growing R&D expenditure by pharmaceutical companies on oncology-based drugs.
By application, the vaccine segment of clinical trials market is set to grow at the fastest pace through the forecast period.
Based on application, the global market is segmented into small applications, vaccines, cell & gene therapy, and others. Companies are enforcing their expertise on COVID-19 vaccine trials to drive the successful commercialization of COVID-19 vaccines. Approximately 194 COVID-19 vaccine candidates were in pre-clinical development, whereas 138 were in the clinical development phase as of January 2022. This has contributed to the segment’s fastest growth.
North America accounted for the largest share of the clinical trials market.
North America accounted for the largest share of the market, followed by Europe. Fast growth in the biologics and biosimilars market, increasing investments towards advancing clinical research is attributive to the large share of North America in market. North America is the largest pharmaceutical market in the world, with many global pharmaceutical and medical device giants, such as Pfizer, Inc. (US), AbbVie, Inc. (US), Abbott Laboratories (US), and Johnson & Johnson (US) headquartered in the region.
To know about the assumptions considered for the study, download the pdf brochure
IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), PPD (US), and ICON Plc (US) are the prominent players operating in the clinical trials market.
Clinical Trials Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2021 |
$38.7 billion |
|
Projected Revenue by 2026 |
$52.0 billion |
|
Revenue Rate |
poised to grow at a CAGR of 6.1% |
|
Market Driver |
Increasing number of clinical trials |
|
Market Opportunity |
Rising demand for specialized testing services among end users |
This research report categorizes the clinical trials market to forecast revenue and analyze trends in each of the following submarkets:
By Phase
- Phase I
- Phase II
- Phase III
- Phase IV
By Service Type
- Protocol Designing
- Site Identification
- Patient Recruitment
- Laboratory Services
-
Bioanalytical Testing Services
- Cell-based Assays
- Virology Testing
- Method Development, Optimization, & Validation
- Serology, Immunogenicity, & Neutralizing Antibodies
- Biomarker Testing Services
- PK/PD (Pharmacokinetics/Pharmacodynamics) Testing Services
- Other Bioanalytical Testing Services
- Analytical Testing Services
- Clinical Trial Supply & Logistic Services
- Decentralized Clinical Services
- Clinical Trial Data Management Services
- Medical Device Testing Services
- Other Clinical Trial Services
By Therapy Area
- Oncology
- Infectious Diseases
- Cardiology
- Neurology
- Women's Health
- Genetic Diseases
- Immunology
- Other Therapy Areas
By Application
- Vaccine
- Cell & Gene Therapy
- Small Molecules
- Other Applications
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- The Middle East and Africa
Recent Developments
- In November 2022, Calit Health Services (Israel) collaborated with IQVIA (US) to work on clinical trial delivery.
- In October 2022, PPD (business of Thermo Fisher Scientific) introduced Decentralized Clinical Trials Network to facilitate participation in decentralized clinical trials.
- In September 2021, Syneos Health collaborated with Ride Health to co-develop non-emergency medical transportation (NEMT) for clinical trial participants.
- In April 2021, Q2 Solutions was acquired by IQVIA; this acquisition is set to strengthen the market position of IQVIA.
Frequently Asked Questions (FAQ):
How big is the global clinical trials market?
Global clinical trials market revenue was estimated at $38.7 billion in 2021 and is projected to reach $52.0 billion by 2026, with a robust growth rate of 6.1% CAGR from 2021 to 2026.
Which major factors are influencing global growth of clinical trials market?
Expanding number of clinical trials along with robust investment in pharmaceutical R&D are some of the key driving factors of the market.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 27)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
FIGURE 1 CLINICAL TRIALS MARKET
1.3.1 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 31)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 3 MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CLINICAL TRIALS IN THE MARKET
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020
FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
FIGURE 7 GLOBAL MARKET: CAGR PROJECTIONS, 2021–2026
FIGURE 8 GLOBAL MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 INSIGHTS FROM PRIMARIES
FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
2.6 RESEARCH ASSUMPTIONS
2.6.1 COVID-19 SPECIFIC ASSUMPTIONS
2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY (Page No. - 43)
FIGURE 12 CLINICAL TRIALS MARKET, BY PHASE, 2021 VS. 2026
FIGURE 13 MARKET, BY THERAPY AREA, 2021 VS. 2026
FIGURE 14 MARKET, BY APPLICATION, 2021 VS. 2026
FIGURE 15 MARKET, BY SERVICE TYPE, 2021 VS. 2026
FIGURE 16 GEOGRAPHICAL SNAPSHOT: GLOBAL MARKET
4 PREMIUM INSIGHTS (Page No. - 47)
4.1 CLINICAL TRIALS MARKET OVERVIEW
FIGURE 17 RISING INVESTMENTS IN THE PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH
4.2 NORTH AMERICA: MARKET SHARE, BY PHASE & COUNTRY (2020)
FIGURE 18 PHASE III SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020
4.3 MARKET, BY BIOANALYTICAL SERVICE TYPE, 2021 VS. 2026
FIGURE 19 CELL-BASED ASSAY SEGMENT CONTINUES TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 50)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 GLOBAL MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing investments in pharmaceutical R&D
FIGURE 21 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026
FIGURE 22 ACTIVE PHARMACEUTICAL PIPELINE, 2011–2021
5.2.1.2 Increasing number of clinical trials
FIGURE 23 NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021)
5.2.1.3 High cost of in-house drug development
FIGURE 24 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010–2020
5.2.1.4 Rising prevalence of orphan and rare diseases
5.2.2 OPPORTUNITIES
5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic
FIGURE 25 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001–2020)
TABLE 2 LIST OF BIOLOGICS APPROVED BY US FDA, 2020
5.2.2.2 Rising demand for specialized testing services among end users
5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies
5.2.3 CHALLENGES
5.2.3.1 Shortage of skilled professionals for clinical trials
5.2.3.2 Requirement of unique analytical testing approaches for innovative drug molecules
5.2.4 MARKET TRENDS
5.2.4.1 Adoption of artificial intelligence-based tools for drug discovery
5.2.4.2 Increasing outsourcing activities in emerging Asian economies
5.2.4.3 Integrated end-to-end R&D service solutions
5.3 RANGES/SCENARIOS
FIGURE 26 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES ON THE GROWTH OF THE GLOBAL MARKET
5.4 IMPACT OF COVID-19 ON THE GLOBAL MARKET
5.5 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 GLOBAL MARKET: PORTER’S FIVE FORCES ANALYSIS
5.5.1 THREAT OF NEW ENTRANTS
5.5.2 THREAT OF SUBSTITUTES
5.5.3 BARGAINING POWER OF BUYERS
5.5.4 BARGAINING POWER OF SUPPLIERS
5.5.5 DEGREE OF COMPETITION
5.6 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
FIGURE 27 REVENUE SHIFT & NEW POCKETS FOR CLINICAL TRIAL SERVICE PROVIDERS
5.7 ECOSYSTEM ANALYSIS
FIGURE 28 ECOSYSTEM ANALYSIS: MARKET
TABLE 4 SUPPLY CHAIN ECOSYSTEM
5.8 REGULATORY ANALYSIS
6 CLINICAL TRIALS MARKET, BY PHASE (Page No. - 69)
6.1 INTRODUCTION
TABLE 5 MARKET, BY PHASE, 2019–2026
FIGURE 29 DRUGS IN THE PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020
6.2 CLINICAL TRIALS PLANNING AND DESIGNING SOLUTION
FIGURE 30 CLINICAL TRIAL PLANNING & DESIGNING
6.3 PHASE I
6.3.1 ROBUST PIPELINE OF PHARMACEUTICAL COMPANIES DRIVES THE GROWTH OF THIS SEGMENT
TABLE 6 EXAMPLES OF PHASE I STUDY OF DRUGS
TABLE 7 PHASE I MARKET, BY REGION, 2019–2026
TABLE 8 NORTH AMERICA: PHASE I MARKET, BY COUNTRY, 2019–2026
TABLE 9 EUROPE: PHASE I MARKET, BY COUNTRY, 2019–2026
TABLE 10 ASIA PACIFIC: PHASE I CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026
6.4 PHASE II
6.4.1 THE LONG DURATION OF PHASE II STUDIES PROVIDES GROWTH OPPORTUNITIES FOR CROS
TABLE 11 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES
TABLE 12 PHASE II MARKET, BY REGION, 2019–2026
TABLE 13 NORTH AMERICA: PHASE II MARKET, BY COUNTRY, 2019–2026
TABLE 14 EUROPE: PHASE II MARKET, BY COUNTRY, 2019–2026
TABLE 15 ASIA PACIFIC: PHASE II MARKET, BY COUNTRY, 2019–2026
6.5 PHASE III
6.5.1 RISING COSTS OF PHASE III TRIALS INCREASE THE DEMAND FOR COST-EFFECTIVE CLINICAL RESEARCH SERVICES
TABLE 16 EXAMPLES OF DRUGS THAT HAVE COMPLETED THE PHASE III STUDY
TABLE 17 PHASE III MARKET, BY REGION, 2019–2026
TABLE 18 NORTH AMERICA: PHASE III MARKET, BY COUNTRY, 2019–2026
TABLE 19 EUROPE: PHASE III MARKET, BY COUNTRY, 2019–2026
TABLE 20 ASIA PACIFIC: PHASE III MARKET, BY COUNTRY, 2019–2026
6.6 PHASE IV
6.6.1 RISING NUMBER OF CLINICAL RESEARCH ENTITIES PROVIDING POST-MARKETING SURVEILLANCE TO DRIVE THE SEGMENT GROWTH
TABLE 21 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES
TABLE 22 PHASE IV CLINICAL TRIALS MARKET, BY REGION, 2019–2026
TABLE 23 NORTH AMERICA: PHASE IV MARKET, BY COUNTRY, 2019–2026
TABLE 24 EUROPE: PHASE IV MARKET, BY COUNTRY, 2019–2026
TABLE 25 ASIA PACIFIC: PHASE IV MARKET, BY COUNTRY, 2019–2026
7 CLINICAL TRIALS MARKET, BY SERVICE TYPE (Page No. - 84)
7.1 INTRODUCTION
TABLE 26 MARKET, BY SERVICE TYPE, 2019–2026
7.2 PROTOCOL DESIGNING
7.2.1 PROTOCOL DESIGNING SERVICES SERVE AS AN EFFECTIVE STRATEGY TO ENSURE RAPID & EFFECTIVE PLANNING FOR CLINICAL TRIAL STUDIES
TABLE 27 PROTOCOL DESIGNING MARKET, BY REGION, 2019–2026
TABLE 28 NORTH AMERICA: PROTOCOL DESIGNING MARKET, BY COUNTRY, 2019–2026
TABLE 29 EUROPE: PROTOCOL DESIGNING MARKET, BY COUNTRY, 2019–2026
TABLE 30 ASIA PACIFIC: PROTOCOL DESIGNING MARKET, BY COUNTRY, 2019–2026
7.3 SITE IDENTIFICATION
7.3.1 NEW DIGITAL TECHNOLOGIES THAT ENABLE DATA VARIABILITY ENHANCES SITE IDENTIFICATION SERVICE EFFICACY
TABLE 31 SITE IDENTIFICATION MARKET, BY REGION, 2019–2026
TABLE 32 NORTH AMERICA: SITE IDENTIFICATION MARKET, BY COUNTRY, 2019–2026
TABLE 33 EUROPE: SITE IDENTIFICATION MARKET, BY COUNTRY, 2019–2026
TABLE 34 ASIA PACIFIC: SITE IDENTIFICATION MARKET, BY COUNTRY, 2019–2026
7.4 PATIENT RECRUITMENT
7.4.1 THE GROWING REQUIREMENT TO WORK WITH A PATIENT-CENTRIC CLINICAL TRIAL COMPANY SUPPORTS THE GROWTH OF THIS SEGMENT
TABLE 35 SOME OF THE PATIENT RECRUITMENT SERVICE PROVIDERS
TABLE 36 PATIENT RECRUITMENT MARKET, BY REGION, 2019–2026
TABLE 37 NORTH AMERICA: PATIENT RECRUITMENT MARKET, BY COUNTRY, 2019–2026
TABLE 38 EUROPE: PATIENT RECRUITMENT MARKET, BY COUNTRY, 2019–2026
TABLE 39 ASIA PACIFIC: PATIENT RECRUITMENT MARKET, BY COUNTRY, 2019–2026
7.5 LABORATORY SERVICES
7.5.1 INCREASING IMPORTANCE OF LABORATORY SERVICES TO ENSURE REGULATORY COMPLIANCE PROPELS THE GROWTH OF THIS SEGMENT
TABLE 40 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 41 LABORATORY SERVICES MARKET, BY REGION, 2019–2026
TABLE 42 NORTH AMERICA: LABORATORY SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 43 EUROPE: LABORATORY SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 44 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY COUNTRY, 2019–2026
7.5.2 ANALYTICAL TESTING SERVICES
7.5.2.1 Increasing demand for analytical testing for drug development to drive the growth of this segment
TABLE 45 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2026
TABLE 46 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 47 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 48 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
7.6 BIOANALYTICAL TESTING SERVICES
7.6.1 HIGH DEMAND FOR BIOANALYTICAL TESTING DUE TO THE GROWING USE OF MACROMOLECULES AND BIOSIMILARS TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 49 BIOANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019–2026
TABLE 50 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2026
TABLE 51 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 52 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 53 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
7.6.2 CELL-BASED ASSAYS
7.6.2.1 Increasing number of service providers offering customized cell-based assay testing services to drive the growth of this segment
TABLE 54 CELL-BASED ASSAYS MARKET, BY REGION, 2019–2026
TABLE 55 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2019–2026
TABLE 56 EUROPE: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2019–2026
TABLE 57 ASIA PACIFIC: CELL-BASED ASSAYS MARKET, BY COUNTRY, 2019–2026
7.6.3 VIROLOGY TESTING
7.6.3.1 Higher uptake of in vitro virology assays in the development of antiviral pharmaceuticals to drive the growth of this segment
TABLE 58 VIROLOGY TESTING MARKET, BY REGION, 2019–2026
TABLE 59 NORTH AMERICA: VIROLOGY TESTING MARKET, BY COUNTRY, 2019–2026
TABLE 60 EUROPE: VIROLOGY TESTING MARKET, BY COUNTRY, 2019–2026
TABLE 61 ASIA PACIFIC: VIROLOGY TESTING MARKET, BY COUNTRY, 2019–2026
7.6.4 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES
7.6.4.1 Rising importance of studies to determine the pharmacokinetic behavior of drug candidates to drive the growth of this segment
TABLE 62 PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY REGION, 2019–2026
TABLE 63 NORTH AMERICA: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 64 EUROPE: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 65 ASIA PACIFIC: PK/PD (PHARMACOKINETICS/PHARMACODYNAMICS) TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
7.6.5 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION
7.6.5.1 Increasing preference of biopharmaceutical companies to outsource method validation services for clinical trials to drive this segment
TABLE 66 METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY REGION, 2019–2026
TABLE 67 NORTH AMERICA: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026
TABLE 68 EUROPE: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026
TABLE 69 ASIA PACIFIC: METHOD DEVELOPMENT, OPTIMIZATION, & VALIDATION MARKET, BY COUNTRY, 2019–2026
7.6.6 SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES
7.6.6.1 High demand for immunogenicity and neutralizing antibody assays in biosimilar development to propel market growth
TABLE 70 USEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES MARKET, BY REGION, 2019–2026
TABLE 71 NORTH AMERICA: SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026
TABLE 72 EUROPE: SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026
TABLE 73 ASIA PACIFIC: SEROLOGY, IMMUNOGENICITY, & NEUTRALIZING ANTIBODIES MARKET, BY COUNTRY, 2019–2026
7.6.7 BIOMARKER TESTING SERVICES
7.6.7.1 Growing emphasis on biomarker testing to develop personalized medicines and companion diagnostics to augment segment growth
TABLE 74 BIOMARKER TESTING SERVICES MARKET, BY REGION, 2019–2026
TABLE 75 NORTH AMERICA: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 76 EUROPE: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 77 ASIA PACIFIC: BIOMARKER TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
7.6.8 OTHER BIOANALYTICAL TESTING SERVICES
TABLE 78 OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019–2026
TABLE 79 NORTH AMERICA: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 80 EUROPE: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 81 ASIA PACIFIC: OTHER BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
7.7 CLINICAL TRIAL DATA MANAGEMENT SERVICES
7.7.1 DATA MANAGEMENT SERVICES SEGMENT IS EXPECTED TO RECORD THE HIGHEST CAGR DURING THE FORECAST PERIOD
TABLE 82 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
TABLE 83 CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY REGION, 2019–2026
TABLE 84 NORTH AMERICA: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 85 EUROPE: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 86 ASIA PACIFIC: CLINICAL TRIAL DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019–2026
7.8 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES
7.8.1 ADVANCED DATA ANALYTICS INCORPORATED IN CLINICAL TRIAL SUPPLY MANAGEMENT IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 87 CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY REGION, 2019–2026
TABLE 88 NORTH AMERICA: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 89 EUROPE: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 90 ASIA PACIFIC: CLINICAL TRIAL SUPPLY & LOGISTIC SERVICES MARKET, BY COUNTRY, 2019–2026
7.9 DECENTRALIZED CLINICAL TRIAL SERVICES
7.9.1 THE SARS-COV-2 OUTBREAK HAS SIGNIFICANTLY CATALYZED THE DEMAND FOR DECENTRALIZED CLINICAL TRIALS
TABLE 91 DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY REGION, 2019–2026
TABLE 92 NORTH AMERICA: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 93 EUROPE: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 94 ASIA PACIFIC: DECENTRALIZED CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026
7.10 MEDICAL DEVICE TESTING SERVICES
7.10.1 INCREASING R&D FOR THE DEVELOPMENT OF ADVANCED MEDICAL DEVICES TO DRIVE THE GROWTH OF THIS MARKET
TABLE 95 MEDICAL DEVICE TESTING SERVICES MARKET, BY REGION, 2019–2026
TABLE 96 NORTH AMERICA: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 97 EUROPE: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 98 ASIA PACIFIC: MEDICAL DEVICE TESTING SERVICES MARKET, BY COUNTRY, 2019–2026
7.11 OTHER CLINICAL TRIAL SERVICES
7.11.1 OTHER CLINICAL TRIAL SERVICES SEGMENT INCLUDES CONSULTING SERVICES, MEDICAL WRITING SERVICES, AND PHARMACOGENOMICS TESTING SERVICES
TABLE 99 OTHER CLINICAL TRIAL SERVICES MARKET, BY REGION, 2019–2026
TABLE 100 NORTH AMERICA: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 101 EUROPE: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026
TABLE 102 ASIA PACIFIC: OTHER CLINICAL TRIAL SERVICES MARKET, BY COUNTRY, 2019–2026
8 CLINICAL TRIALS MARKET, BY THERAPY AREA (Page No. - 122)
8.1 INTRODUCTION
TABLE 103 CLINICAL TRIALS MARKET, BY THERAPY AREA, 2019–2026
8.2 ONCOLOGY
8.2.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
FIGURE 31 GLOBAL CANCER INCIDENCE, BY TYPE (2020)
FIGURE 32 ONCOLOGY CLINICAL TRIALS GLOBALLY, 2010-2018 (THOUSAND)
TABLE 104 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)
TABLE 105 GLOBAL MARKET FOR ONCOLOGY, BY REGION, 2019–2026
TABLE 106 NORTH AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026
TABLE 107 EUROPE: MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026
TABLE 108 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026
8.3 INFECTIOUS DISEASES
8.3.1 INFECTIOUS DISEASES SEGMENT TO REGISTER THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD
TABLE 109 CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026
TABLE 110 NORTH AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026
TABLE 111 EUROPE: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026
TABLE 112 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026
8.4 NEUROLOGY
8.4.1 INCREASING INVESTMENTS IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
TABLE 113 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
TABLE 114 GLOBAL MARKET FOR NEUROLOGY, BY REGION, 2019–2026
TABLE 115 NORTH AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026
TABLE 116 EUROPE: MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026
TABLE 117 ASIA PACIFIC: MARKET FOR NEUROLOGY, BY COUNTRY, 2019–2026
8.5 IMMUNOLOGY
8.5.1 GROWING PIPELINE OF IMMUNOLOGICAL DRUGS HAS RESULTED IN INCREASING OUTSOURCING ACTIVITIES
TABLE 118 CLINICAL TRIALS MARKET FOR IMMUNOLOGY, BY REGION, 2019–2026
TABLE 119 NORTH AMERICA: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026
TABLE 120 EUROPE: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026
TABLE 121 ASIA PACIFIC: MARKET FOR IMMUNOLOGY, BY COUNTRY, 2019–2026
8.6 CARDIOLOGY
8.6.1 HIGH MORTALITY RATES ARE DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
TABLE 122 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)
TABLE 123 GLOBAL MARKET FOR CARDIOLOGY, BY REGION, 2019–2026
TABLE 124 NORTH AMERICA: MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026
TABLE 125 EUROPE: MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026
TABLE 126 ASIA PACIFIC: MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026
8.7 GENETIC DISEASES
8.7.1 PROMISING DRUGS IN THE PIPELINE FOR RARE DISEASES TO SUPPORT MARKET GROWTH
TABLE 127 GLOBAL MARKET FOR GENETIC DISEASES, BY REGION, 2019–2026
TABLE 128 NORTH AMERICA: MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019–2026
TABLE 129 EUROPE: MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019–2026
TABLE 130 ASIA PACIFIC: MARKET FOR GENETIC DISEASES, BY COUNTRY, 2019–2026
8.8 WOMEN’S HEALTH
8.8.1 THE RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN DRIVES MARKET GROWTH
TABLE 131 CLINICAL TRIALS MARKET FOR WOMEN’S HEALTH, BY REGION, 2019–2026
TABLE 132 NORTH AMERICA: MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019–2026
TABLE 133 EUROPE: MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019–2026
TABLE 134 ASIA PACIFIC: MARKET FOR WOMEN’S HEALTH, BY COUNTRY, 2019–2026
8.9 OTHER THERAPY AREAS
FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES, 2000-2045 (MILLION)
TABLE 135 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020)
TABLE 136 GLOBAL MARKET FOR OTHER THERAPY AREAS, BY REGION, 2019–2026
TABLE 137 NORTH AMERICA: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2019–2026
TABLE 138 EUROPE: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2019–2026
TABLE 139 ASIA PACIFIC: MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2019–2026
9 CLINICAL TRIALS MARKET, BY APPLICATION (Page No. - 143)
9.1 INTRODUCTION
TABLE 140 CLINICAL TRIAL MARKET, BY APPLICATION, 2019–2026
9.2 SMALL MOLECULE
9.2.1 INCREASING INVESTMENTS BY VIRTUAL AND SMALLER COMPANIES TO DRIVE SMALL MOLECULE DEVELOPMENT PROJECTS SUPPORTS THE GROWTH OF THIS SEGMENT
FIGURE 34 SMALL MOLECULE PIPELINE: NEW CHEMICAL ENTITY, 2014-2019
TABLE 141 CLINICAL TRIALS MARKET FOR SMALL MOLECULES, BY REGION, 2019–2026
TABLE 142 NORTH AMERICA: MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026
TABLE 143 EUROPE: MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026
TABLE 144 ASIA PACIFIC: CLINICAL TRIAL MARKET FOR SMALL MOLECULES, BY COUNTRY, 2019–2026
9.3 VACCINES
9.3.1 OUTBREAK OF THE COVID-19 PANDEMIC IS EXPECTED TO EMERGE AS A MARKET DISRUPTOR, IMPOSING LONG-TERM POSITIVE EFFECTS ON THE INDUSTRY OPERATIONS
FIGURE 35 COVID-19 VACCINE CANDIDATES IN CLINICAL DEVELOPMENT, BY PHASE (AS OF JANUARY 2022)
TABLE 145 MARKET FOR VACCINES, BY REGION, 2019–2026
TABLE 146 NORTH AMERICA: MARKET FOR VACCINES, BY COUNTRY, 2019–2026
TABLE 147 EUROPE: MARKET FOR VACCINES, BY COUNTRY, 2019–2026
TABLE 148 ASIA PACIFIC: MARKET FOR VACCINES, BY COUNTRY, 2019–2026
9.4 CELL & GENE THERAPY
9.4.1 THE RISING TREND OF OUTSOURCING SERVICES AND THE ONGOING EFFORTS OF SERVICE PROVIDERS TO EXPAND OFFERINGS DRIVES THE SEGMENT GROWTH
FIGURE 36 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY INDICATION (AS OF 2020)
FIGURE 37 ACTIVE CLINICAL TRIALS FOR CELL & GENE THERAPY, BY PHASE (2020)
TABLE 149 CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY REGION, 2019–2026
TABLE 150 NORTH AMERICA: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026
TABLE 151 EUROPE: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026
TABLE 152 ASIA PACIFIC: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2019–2026
9.5 OTHER APPLICATIONS
9.5.1 INCREASE IN R&D FOR THE DEVELOPMENT OF HORMONES AND BLOOD COMPONENTS SUPPORTS MARKET GROWTH
TABLE 153 MARKET FOR OTHER APPLICATIONS, BY REGION, 2019–2026
TABLE 154 NORTH AMERICA: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026
TABLE 155 EUROPE: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026
TABLE 156 ASIA PACIFIC: MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026
10 CLINICAL TRIALS MARKET, BY REGION (Page No. - 155)
10.1 INTRODUCTION
TABLE 157 CLINICAL TRIALS MARKET, BY REGION, 2019–2026
10.2 NORTH AMERICA
FIGURE 38 NORTH AMERICA SNAPSHOT
TABLE 158 NORTH AMERICA: MARKET, BY COUNTRY, 2019–2026
TABLE 159 NORTH AMERICA: MARKET, BY PHASE, 2019–2026
TABLE 160 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY SERVICE TYPE, 2019–2026
TABLE 161 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 162 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY THERAPY AREA, 2019–2026
TABLE 163 NORTH AMERICA: MARKET, BY APPLICATION, 2019–2026
10.2.1 US
10.2.1.1 Robust clinical research activities to become a key factor supporting the US market growth
FIGURE 39 US CONTINUES TO DOMINATE THE DISTRIBUTION OF R&D COMPANIES BY REGION (2020 VS. 2019)
TABLE 164 US: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 165 US: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 166 US: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 167 US: MARKET, BY THERAPY AREA, 2019–2026
TABLE 168 US: MARKET, BY APPLICATION, 2019–2026
10.2.2 CANADA
10.2.2.1 Increasing number of clinical trials in Canada to support market growth
TABLE 169 CANADA: MARKET, BY PHASE, 2019–2026
TABLE 170 CANADA: CLINICAL TRIALS MARKET, BY SERVICE TYPE, 2019–2026
TABLE 171 CANADA: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 172 CANADA: MARKET, BY THERAPY AREA, 2019–2026
TABLE 173 CANADA: MARKET, BY APPLICATION, 2019–2026
10.3 EUROPE
FIGURE 40 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018)
TABLE 174 EUROPE: CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026
TABLE 175 EUROPE: MARKET, BY PHASE, 2019–2026
TABLE 176 EUROPE: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 177 EUROPE: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 178 EUROPE: MARKET, BY THERAPY AREA, 2019–2026
TABLE 179 EUROPE: MARKET, BY APPLICATION, 2019–2026
10.3.1 GERMANY
10.3.1.1 Government support and flexible labor laws have made Germany a favorable location for clinical trials
TABLE 180 GERMANY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 181 GERMANY: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 182 GERMANY: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 183 GERMANY: MARKET, BY THERAPY AREA, 2019–2026
TABLE 184 GERMANY: MARKET, BY APPLICATION, 2019–2026
10.3.2 UK
10.3.2.1 Investments by pharmaceutical sponsors in the UK for drug discovery services to support market growth
FIGURE 41 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013–2017
TABLE 185 UK: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 186 UK: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 187 UK: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 188 UK: MARKET, BY THERAPY AREA, 2019–2026
TABLE 189 UK: MARKET, BY APPLICATION, 2019–2026
10.3.3 FRANCE
10.3.3.1 High number of oncology clinical trials in France is expected to drive market growth in France
TABLE 190 FRANCE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 191 FRANCE: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 192 FRANCE: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 193 FRANCE: MARKET, BY THERAPY AREA, 2019–2026
TABLE 194 FRANCE: MARKET, BY APPLICATION, 2019–2026
10.3.4 ITALY
10.3.4.1 Low drug approval times along with the growing number of clinical trials in Italy to drive market growth
TABLE 195 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
TABLE 196 ITALY: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 197 ITALY: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 198 ITALY: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 199 ITALY: MARKET, BY THERAPY AREA, 2019–2026
TABLE 200 ITALY: MARKET, BY APPLICATION, 2019–2026
10.3.5 SPAIN
10.3.5.1 Rising R&D expenditure to boost market growth for clinical trials in Spain
FIGURE 42 SPAIN: PHARMACEUTICAL R&D EXPENDITURE , 2011–2017
TABLE 201 SPAIN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 202 SPAIN: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 203 SPAIN: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 204 SPAIN: MARKET, BY THERAPY AREA, 2019–2026
TABLE 205 SPAIN: MARKET, BY APPLICATION, 2019–2026
10.3.6 REST OF EUROPE (ROE)
TABLE 206 ROE: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 207 ROE: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 208 ROE: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 209 ROE: MARKET, BY THERAPY AREA, 2019–2026
TABLE 210 ROE: MARKET, BY MOLECULE, 2019–2026
10.4 ASIA PACIFIC (APAC)
FIGURE 43 ASIA PACIFIC SNAPSHOT
TABLE 211 ASIA PACIFIC: CLINICAL TRIALS MARKET, BY COUNTRY, 2019–2026
TABLE 212 ASIA PACIFIC: MARKET, BY PHASE, 2019–2026
TABLE 213 ASIA PACIFIC: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 214 ASIA PACIFIC: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 215 ASIA PACIFIC: MARKET, BY THERAPY AREA, 2019–2026
TABLE 216 ASIA PACIFIC: MARKET, BY APPLICATION, 2019–2026
10.4.1 CHINA
10.4.1.1 China dominates the clinical trials services market owing to a robust pharmaceutical industry and the presence of prominent clinical trial service providers
TABLE 217 CHINA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 218 CHINA: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 219 CHINA: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 220 CHINA: MARKET, BY THERAPY AREA, 2019–2026
TABLE 221 CHINA: MARKET, BY APPLICATION, 2019–2026
10.4.2 JAPAN
10.4.2.1 Strong focus on R&D activities in Japan is expected to drive market growth
TABLE 222 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 223 JAPAN: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 224 JAPAN: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 225 JAPAN: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 226 JAPAN: MARKET, BY THERAPY AREA, 2019–2026
TABLE 227 JAPAN: MARKET, BY APPLICATION, 2019–2026
10.4.3 INDIA
10.4.3.1 Growing pharmaceutical industry in India to drive the market growth for clinical trials
TABLE 228 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 229 INDIA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 230 INDIA: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 231 INDIA: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 232 INDIA: MARKET, BY THERAPY AREA, 2019–2026
TABLE 233 INDIA: MARKET, BY APPLICATION, 2019–2026
10.4.4 REST OF ASIA PACIFIC
TABLE 234 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA, BY THERAPEUTIC AREA, 2017 VS. 2019
TABLE 235 ROAPAC: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 236 ROAPAC: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 237 ROAPAC: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 238 ROAPAC: MARKET, BY THERAPY AREA, 2019–2026
TABLE 239 ROAPAC: MARKET, BY APPLICATION, 2019–2026
10.5 LATIN AMERICA
10.5.1 GROWING R&D EXPENDITURE IN THE PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE THE MARKET GROWTH IN LATIN AMERICA
TABLE 240 LATIN AMERICA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 241 LATIN AMERICA: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 242 LATIN AMERICA: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 243 LATIN AMERICA: MARKET, BY THERAPY AREA, 2019–2026
TABLE 244 LATIN AMERICA: MARKET, BY APPLICATION, 2019–2026
10.6 MIDDLE EAST & AFRICA
10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE THE MARKET GROWTH IN MIDDLE EAST & AFRICA
TABLE 245 MEA: CLINICAL TRIALS MARKET, BY PHASE, 2019–2026
TABLE 246 MEA: MARKET, BY SERVICE TYPE, 2019–2026
TABLE 247 MEA: MARKET, BY BIOANALYTICAL SERVICES, 2019–2026
TABLE 248 MEA: MARKET, BY THERAPY AREA, 2019–2026
TABLE 249 MEA: MARKET, BY APPLICATION, 2019–2026
11 COMPETITIVE LANDSCAPE (Page No. - 211)
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
FIGURE 44 CLINICAL TRIALS MARKET: STRATEGIES ADOPTED
11.3 MARKET SHARE ANALYSIS
FIGURE 45 GLOBAL MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020)
11.4 COMPANY EVALUATION QUADRANT
11.4.1 STARS
11.4.2 EMERGING LEADERS
11.4.3 PERVASIVE PLAYERS
11.4.4 PARTICIPANTS
FIGURE 46 GLOBAL MARKET: COMPANY EVALUATION MATRIX, 2020
11.5 COMPETITIVE BENCHMARKING
11.5.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES)
FIGURE 47 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE GLOBAL MARKET
11.5.2 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
FIGURE 48 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN THE GLOBAL MARKET
11.6 COMPETITIVE SCENARIO AND TRENDS
11.6.1 SERVICES LAUNCHES
TABLE 250 GLOBAL MARKET: SERVICE LAUNCHES (JANUARY 2017-NOVEMBER 2020)
11.6.2 DEALS
TABLE 251 GLOBAL MARKET: DEALS (JANUARY 2017-SEPTEMBER 2021)
11.6.3 OTHER DEVELOPMENTS
TABLE 252 MARKET: EXPANSIONS (JANUARY 2017-NOVEMBER 2020)
12 COMPANY PROFILES (Page No. - 222)
12.1 KEY COMPANIES
(Business Overview, Services, Recent Developments, MnM View)*
12.1.1 IQVIA
TABLE 253 IQVIA: BUSINESS OVERVIEW
FIGURE 49 IQVIA: COMPANY SNAPSHOT
TABLE 254 IQVIA: SERVICE OFFERINGS
TABLE 255 IQVIA: SERVICE LAUNCHES
TABLE 256 IQVIA: DEALS
TABLE 257 IQVIA: OTHER DEVELOPMENTS
12.1.2 LABCORP DRUG DEVELOPMENT (COVANCE)
TABLE 258 LABCORP: BUSINESS OVERVIEW
FIGURE 50 LABCORP: COMPANY SNAPSHOT
TABLE 259 LABCORP: SERVICE OFFERINGS
TABLE 260 LABCORP: SERVICE LAUNCHES
TABLE 261 LABCORP: DEALS
TABLE 262 LABCORP: EXPANSIONS
12.1.3 SYNEOS HEALTH INC.
TABLE 263 SYNEOS HEALTH INC.: BUSINESS OVERVIEW
FIGURE 51 SYNEOS HEALTH INC.: COMPANY SNAPSHOT
TABLE 264 SYNEOS HEALTH INC.: SERVICE OFFERINGS
TABLE 265 SYNEOS HEALTH INC: SERVICE LAUNCHES
TABLE 266 SYNEOS HEALTH INC.: DEALS
12.1.4 WUXI APPTEC
TABLE 267 WUXI APPTEC: BUSINESS OVERVIEW
FIGURE 52 WUXI APPTEC: COMPANY SNAPSHOT
TABLE 268 WUXI APPTEC: SERVICE OFFERINGS
TABLE 269 WUXI APPTEC: SERVICE LAUNCHES
TABLE 270 WUXI APPTEC: DEALS
TABLE 271 WUXI APPTEC: EXPANSIONS
12.1.5 CHARLES RIVER LABORATORIES
TABLE 272 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 53 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
TABLE 273 CHARLES RIVER LABORATORIES: SERVICE OFFERINGS
TABLE 274 CHARLES RIVER LABORATORIES: DEALS
TABLE 275 CHARLES RIVER LABORATORIES: EXPANSIONS
12.1.6 PAREXEL INTERNATIONAL
TABLE 276 PAREXEL INTERNATIONAL: BUSINESS OVERVIEW
TABLE 277 PAREXEL INTERNATIONAL: SERVICE OFFERINGS
TABLE 278 PAREXEL INTERNATIONAL: SERVICE LAUNCHES
TABLE 279 PAREXEL INTERNATIONAL: DEALS
TABLE 280 PAREXEL INTERNATIONAL: EXPANSIONS
12.1.7 PRA HEALTH SCIENCES
TABLE 281 PRA HEALTH SCIENCES: BUSINESS OVERVIEW
FIGURE 54 PRA HEALTH SCIENCES: COMPANY SNAPSHOT
TABLE 282 PRA HEALTH SCIENCES: SERVICE OFFERINGS
TABLE 283 PRA HEALTH SCIENCES: SERVICE LAUNCHES
TABLE 284 PRA HEALTH SCIENCES: DEALS
TABLE 285 PRA HEALTH SCIENCES: EXPANSIONS
12.1.8 PPD INC
TABLE 286 PPD INC: BUSINESS OVERVIEW
FIGURE 55 PPD INC: COMPANY SNAPSHOT
TABLE 287 PPD INC: SERVICE OFFERINGS
TABLE 288 PPD: SERVICE LAUNCHES
TABLE 289 PPD: DEALS
TABLE 290 PPD: EXPANSIONS
12.1.9 ICON PLC
TABLE 291 ICON PLC: BUSINESS OVERVIEW
FIGURE 56 ICON PLC: COMPANY SNAPSHOT
TABLE 292 ICON PLC: SERVICE OFFERINGS
TABLE 293 ICON PLC: SERVICE LAUNCHES
TABLE 294 ICON PLC: DEALS
12.1.10 MEDPACE HOLDINGS INC
TABLE 295 MEDPACE HOLDINGS INC: BUSINESS OVERVIEW
FIGURE 57 MEDPACE HOLDINGS INC: COMPANY SNAPSHOT
TABLE 296 MEDPACE HOLDINGS INC: SERVICE OFFERINGS
TABLE 297 MEDPACE HOLDINGS INC: DEALS
TABLE 298 MEDPACE HOLDINGS INC: EXPANSION
12.1.11 ACM GLOBAL LABORATORIES
TABLE 299 ACM GLOBAL LABORATORIES: BUSINESS OVERVIEW
TABLE 300 ACM GLOBAL LABORATORIES: SERVICE OFFERINGS
12.1.12 ADVANCED CLINICAL
TABLE 301 ADVANCED CLINICAL: BUSINESS OVERVIEW
TABLE 302 ADVANCED CLINICAL: SERVICE OFFERINGS
12.1.13 SGS
TABLE 303 SGS: BUSINESS OVERVIEW
FIGURE 58 SGS: COMPANY SNAPSHOT
TABLE 304 SGS: SERVICE OFFERINGS
TABLE 305 SGS: DEALS
12.1.14 FRONTAGE HOLDINGS CORPORATION
TABLE 306 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 59 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT
TABLE 307 FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS
TABLE 308 FRONTAGE HOLDINGS CORPORATION: DEALS
TABLE 309 FRONTAGE HOLDINGS CORPORATION: EXPANSION
12.1.15 PSI CRO AG
TABLE 310 PSI CRO AG: BUSINESS OVERVIEW
TABLE 311 PSI CRO AG: SERVICE OFFERINGS
TABLE 312 PSI CRO AG: EXPANSIONS
12.1.16 BIO AGILE THERAPEUTICS
TABLE 313 BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW
TABLE 314 BIO AGILE THERAPEUTICS: SERVICE OFFERINGS
12.2 OTHER PLAYERS
12.2.1 AZELIX
TABLE 315 AZELIX: COMPANY OVERVIEW
12.2.2 CTSERV
TABLE 316 CTSERV: COMPANY OVERVIEW
12.2.3 PEPGRA
TABLE 317 PEPGRA: COMPANY OVERVIEW
12.2.4 AXCENT ADVANCED ANALYTICS (A3)
TABLE 318 AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW
12.2.5 DOVE QUALITY SOLUTIONS
TABLE 319 DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW
12.2.6 FIRMA CLINICAL RESEARCH
TABLE 320 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW
12.2.7 CELERION
TABLE 321 CELERION: COMPANY OVERVIEW
12.2.8 NOVOTECH HEALTH HOLDINGS
TABLE 322 NOVOTECH HEALTH HOLDINGS: COMPANY OVERVIEW
12.2.9 GENETICIST INC.
TABLE 323 GENETICIST INC.: COMPANY OVERVIEW
12.2.10 LINICAL AMERICAS
TABLE 324 LINICAL AMERICAS: COMPANY OVERVIEW
*Details on Business Overview, Services, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 297)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORT
13.5 AUTHOR DETAILS
This technical, market-oriented, and financial study of the global clinical trials market involved extensive secondary sources, directories, and databases to identify and collect relevant information. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess market growth prospects. The global size of the market (estimated through various research approaches) was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Data
The secondary sources referred to for this research study include publications from government sources, such as the Association of Clinical Research Organization (ACRO), Clinical Research Society (CRS), Clinical Research Association of Canada (CRAC), Association of International Contract Research Organizations (AICROS), Clinical and Contract Research Association (CCRA), American Association of Pharmaceutical Scientists (AAPS), Eurostat, Food and Drug Administration (FDA), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan CRO Association, Chinese Association for Laboratory Animal Sciences (CALAS), and Indian Society for Clinical Research. Secondary sources include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global market, which was validated through primary research.
Primary Data
Extensive primary research was conducted after acquiring basic knowledge about the global market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes) and supply-side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from tier 1 and tier 2 companies engaged in offering services) across five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 40% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Primary research was used in this report to:
- Validate the market segmentation defined through a product and service portfolio assessment of the leading players in the clinical trials market
- Understand key industry trends and issues defining the strategic growth objectives of market players
- Gather both demand- and supply-side validation of the key factors affecting the market growth (such as market drivers, challenges, and opportunities)
- Validate assumptions for the market sizing and forecasting model used for this study
- Understand the market position of leading players in the market and their market shares/rankings
To know about the assumptions considered for the study, download the pdf brochure
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total clinical trials market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Report Objectives
- To define, describe, and forecast the global clinical trials market based on phase, service type, therapy area, application, and region.
- To provide detailed information regarding the major factors influencing the market growth (drivers, opportunities, and industry-specific challenges) along with the current trends
- To strategically analyze micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
-
To forecast the revenue of market segments with respect to five major regions:
North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa - To profile key players and comprehensively analyze their market shares and core competencies
- To track and analyze competitive developments in the market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and research & development activities.
Available Customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the rest of Europe market, by country
- Further breakdown of the rest of Asia Pacific market, by country
- Further breakdown of the Latin American and Middle Eastern & African market, by country
Company Information
Detailed analysis and profiling of additional market players (up to 5) inclusive of:
- Business Overview
- Financial Information
- Product Offered
- Developments (Last three years)
Growth opportunities and latent adjacency in Clinical Trials Market
Which segment, Based on the therapy area, accounted for the major share of the global Clinical Trials Market?
Can you share the detailed report on the geographical analysis of the global Clinical Trials Market?
Which of the global leaders holds the largest share of the global Clinical Trials Market?